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NUCLEOTIDE OR NUCLEOSIDE
PHOTOAFFINITY COMPOUND MODIFIED
ANTIBODIES, METHODS FOR THEIR
MANUFACTURE AND USE THEREOF AS

can be used as speci?c immunoprecipitating agents to detect

the presence of an antigen which they speci?cally bind by
coupling the antigen-antibody reaction with suitable detec
tion techniques such as labeling with radioisotopes or with
detectable enzymes (RIA. EMIT. and ELISA). Antibodies
are thus the foundation of immunodiagnostic tests for many

DIAGNOSTICS AND THERAPEUTICS

antigenic substances.

This application is a divisional. of Application Ser. No.
08/208.822?led Mar. 11. 1994 now U.S. Pat. No. 5.596.081.

CROSS REFERENCE TO RELATED

Another important application of antibodies involves their
10

APPLICANTS

use as therapeutics. The therapeutic administration of anti
bodies has recently been described for the treatment of
numerous disease conditions including cancer. and numer
ous infectious diseases.

This application relates to U.S. Ser. No. 081138.109 ?led
on Oct. 20. 1993. This application is incorporated by refer
ence in is its entirety herein.

The therapeutic usage of antibodies has been the focus of
greater interest since the development of monoclonal

antibody/hybridoma technology by Kohler and Milstein
FIELD OF THE INVENTION

(Proc. Natl. Acad. Sci. USA, 772197 (1980)). Monoclonal
antibodies. which are produced by hybridomas. are prefer

The present invention relates to the discovery of novel site
or sites on antibodies having high affinity for nucleotide or

able to polyclonal antibodies because of their greater anti
genic speci?city. Monoclonal antibodies have a lesser ten
dency than polyclonal antibodies to non-speci?cally bind to
non-targeted moieties. e.g.. cells which do not express the

nucleoside photoa?inity compounds. The present invention
further relates to the use of these novel site or sites as a target

for photoa?inity labeling using nucleotide or nucleoside
photoa?inity compounds and for the attachment of mol
ecules having a particular chemical or biological activity. In

corresponding antigen. However. monoclonal antibodies

particular. the present invention concerns a site or sites on 25

antibodies having high a?inity for purine or purine deriva

antibody produced or stop secreting the antibody altogether.
In an effort to obviate some of the problems associated
30

which have a?inity for these sites and for the attachment of

with polyclonal and monoclonal antibodies. and further to
obtain a reproducible supply of antibodies having a de?ned

binding speci?city. researchers have used recombinant tech

molecules having a particular chemical or biological activ

ity.
The present invention further relates to compositions,
methods. and test kits which contain or use the subject

hybridoma (mammalian) origin. Also. hybridoma cell lines
tend to be unstable and may alter the production of the

tive containing photoa?inity compounds. e. g.. ATP- or G1?
analog photoat?nity compounds and the use of these sites as
targets for purine or purine derivative photoa?inity com

pounds or other heterocyclic base containing compounds

still suffer from some disadvantages. e.g.. they tend to be
contaminated with other proteins and cellular materials of

35

niques to produce immunoglobulins which are analogous or
modified in comparison to antibodies normally found in
vertebrate systems. For example. U.S. Pat. No. 4.816397
issued on Mar. 28. 1989 to Boss et al. and U.S. Pat No.
4.816.567 issued on Mar. 28. 1989 to Cabilly et al. disclose

nucleotide photoa?inity labeled antibodies. The present
invention still further relates to novel compositions, methods
and test kits which use the procedure of photoa?inity label
ing with nucleotide a?inity probes, to attach molecules
having a desired chemical or biological activity to antibody

recombinant immunoglobulins and immunoglobulin
fragments. and methods for their production.
To enhance or modify the properties of recombinant
antibodies. it is further known to produce mutant or chimeric

molecules.

antibodies, e.g.. which comprise sequences from several
di?erent mammalian species or bispeci?c antibodies which

BACKGROUND OF THE INVENTION

Antibodies are speci?c immunoglobulin molecules pro
duced by vertebrate immune systems in response to chal

comprise antigenic binding sequences from two ditferent
45

lenge by foreign proteins. glycoproteins. cells, or other
typically foreign substances. The sequence of events which
permits an organism to overcome invasion by foreign cells
or to rid the system of foreign substances is at least partially
understood. An important part of this process is the manu
facture of antibodies which bind speci?cally to a particular

foreign antigenic substance. The binding speci?city of such
polypeptides to a particular antigen is highly re?ned, and the
multitude of speci?cities capable of being generated by an
individual vertebrate is remarkable in its complexity and

55

variability. Thousands of antigens are capable of eliciting
antibody responses. each almost exclusively directed to the

Immunoglobulins include both antibodies. as above
described. and analogous protein substances which lack
antigen speci?city. The latter are produced at low levels by
the lymph system and in increased levels by myelomas.
Antibodies are produced by B lymphocytes and represent

their antigen speci?city. antibodies comprise numerous

diagnostic and therapeutic applications. For example. they

diagnostic or therapeutic agents. it is conventional to
covalently bind or complex desired molecules thereto. in
particular e?’ector or reporter molecules. Eifector molecules

essentially comprise molecules having a desired activity.
e.g.. cytotoxic activity. By contrast. a reporter molecule is

particular antigen which elicited it.

the humoral arm of the immune defense system. Because of

antibodies. For example. humanized antibodies which com

prise antigen-binding sites from a non-human species
(typically routine) but wherein the remainder of the immu
noglobulin is of human origin are known in the art. and have
been reported to have signi?cant potential as therapeutics
because of their reduced antigenicity. It is further known to
produce recombinant antibodies of single chain form. which
completely lack constant domain sequences but which bind
antigen. (See, Bird et al.. Science, 242. 423-426 (1988)).
In order to increase the e?icacy of antibody molecules as

de?ned as any moiety which may be detected using an assay.
Examples of effector molecules which have been attached to

antibodies include by way of example. toxins. anti-tumor
gents. therapeutic enzymes. radionuclides. antiviral agents.

chelating agents. cytokines. growth factors. and polynucle
65

otides. Examples of reporter molecules which have been

conjugated to antibodies include. by way of example.
enzymes. radiolabels. ?uorescent labels. phosphorescent
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molecules. chemiluminescent molecules. chromophores,

Another known method of site-speci?c attachment of
molecules to antibodies comprises the reaction of antibodies

luminescent molecules. and colored particles.
While it is desirable to attach molecules to antibodies in

with hapten-based a?inity labels. Essentially. hapten-based

order to impart a desired activity to the antibody or provide
for the detection thereof, the attachment of desired mol
ecules to antibodies is not always possible to carry out
conveniently. or effectively, because such attachment may

gen reaction. However. this is disadvantageous since it

results in loss of antigen binding by the antibody conjugate.

result in loss of antibody activity. In particular, current
methods for generating radiolabeled antibodies for diagnos

Thus. based on the foregoing. it is clear that there still
exists a signi?cant need in the an for improved methods of

tic and therapeutic use suffer from such limitations. For

attaching molecules to antibodies, in particular elfector or
reporter molecules, which are site-speci?c and which more

a?inity labels react with amino acids in the antigen binding

site. thereby destroying this site and blocking speci?c anti

example. the ratio of target-speci?c versus non-speci?c
uptake of radiolabeled antibodies used in tumor imaging is

over result in antibody conjugates having substantially unal
tered structure and biological activity. most especially anti

often low. resulting in unclear images or missing tumor sites.
Moreover. the low therapeutic index of radiolabeled anti
bodies limits the use of high radiation doses in radiation

gen binding activity.
Molecules containing azido groups have been shown to
form covalent bonds to proteins through reactive nitrene

therapy.

intermediates. generated by low intensity ultraviolet light.

The underlying reason for such problems is largely
because the labeling chemistry for introduction of the radio
label results in the partial denaturation of the antibody

Potter & Haley, Meth. in EnzymoL, 91.613-633 (1983). In
particular, 2- and 8- azido analogues of purine nucleotides
have been used as site directed photoprobes to identify
nucleotide binding proteins in crude cell extracts. Owens &
Haley, J. Biol. Chem, 259:14843-14848 (1987); Atherton et
al., Biol. of Reproduction, 32, 155-171 (1985). The 2— and

structure. which in turn causes the antibodies to aggregate in

vivo or in vitro. Aggregated and damaged immunoglobulins
are recognized by scavenger cells in the body, such as

macrophages and Kupffer cells in the liver and lung.
Another problem is that most coupling strategies result in
non site-speci?c attachment of the molecule to the antibody
molecule. in particular. attachment may occur at antibody
residues which are essential for antigen binding or other
antibody functions. For instance, a known site of attachment
of desired molecules to antibody molecules comprise thiol
groups. since thiol groups occur naturally in proteins as

8-azido nucleotides have also been used to map nucleotide

30

binding domains of puri?ed proteins. Khatoon et al.. Ann. of
Neurology, 26. 210-219 (1989); King et al.. J. Biol. Chem,
269, 10210-10218 (1989); and Dholakia et al.. J. Biol.
Chem, 264. 20638-20642 (1989).
Photoa?inity probes have been used to determine speci?c
nucleotide binding sites on a biologically active recombinant

peptide molecule. Campbell et al.. PNAS. 87, 1243-1246
(1990). The probes have also been used to study enzyme
kinetics of puri?ed proteins. Kim et al.. J. Biol. Chem, 265.
3636-3641 (1990).
Recently, ATP or GTP analog photoa?inity labeled probes

cysteine residues. However, such residues are relatively
uncommon. are often inside the molecule and are frequently

involved in forming disul?de bridges within or between
protein molecules. Thus. there is a danger that if a naturally
occm-ring cysteine residue is used as a site of attachment. it
will interfere with the normal folding and stabilization of the

have been used to detect a glutarnine synthetase nucleotide

antibody protein.

binding protein having an apparent molecular weight of
about 42.000 proteins to aid in the diagnosis of Alzheimer’s

In an eifort to obviate such problems, alternative strate

gies have been developed which provide for site-selective

disease in a mammal. U.S. Ser. No. 08/138,109 ?led on Oct.

attachment of a desired molecules to antibodies. without loss

20, 1993 by Haley et al. Additionally. ATP or GTP analog
photoa?inity-labeling reagents have been disclosed for use
in the detection of particular nucleotide binding proteins to

of antigen-binding activity. For example, it is known to

produce recombinant antibodies comprising cysteine resi

aid in the diagnosis of cancer in a mammal and in the

dues introduced into their surface structure to provide a thiol
group which is available for covalent binding to an etfector
or reporter molecule. This method has been reported to
facilitate the site-speci?c attachment of desired molecules

diagnosis of leukemia in a mammal. (Id.)
However, while it had been previously lcnown to use

nucleotide photoa?inity probes, and speci?cally purine con
taining photoaf?nity analogs (GI‘P- and ATP-analogs). to

without loss of antigen binding properties. (See. U.S. Pat.
No. 5.219.996 issued on Jun. 15, 1993 to Bodmer et al.)
However, this is not always possible or convenient since it

50

obviously requires the possession of a recombinant DNA

encoding the particular antibody.

map nucleotide binding domains of puri?ed proteins and to
identify speci?c nucleotide binding sites on recombinant
peptide molecules, the use of nucleotide photoaf?nity probes
to label antibodies has not been previously reported in the
literature. This is essentially because it had not been previ

It has further been proposed to derivatize immunoglobu

region of an immunoglobulin. using reaction conditions
which purportedly do not result in alteration of the antibody

ously known that antibody molecules comprise nucleotide
photoa?inity sites, and in particular. sites having high a?in
ity for purine, azidopurine and other similar heterocyclic

combining site. Antibody conjugates produced according to

bases. which may be e?iciently photolabeled using appro

this methodology are disclosed to exhibit improved

priate photoa?nity probes.

lins by selectively introducing sulfhydryl groups in the Fc

longevity, speci?city and sensitivity (U.S. Pat. No. 5.196,

OBJECTS AND SUMMARY OF THE
INVENTION
It is. therefore, an object of this invention to identify
nucleotide or nucleoside a?inity sites on antibodies which

066 issued on Mar. 2. 1993 to Bieniarz et al.).

Site-speci?c attachment of e?ector or reporter molecules.
wherein the reporter or eifector molecule is conjugated to a

carbohydrate residue in the Fc region has also been dis
closed in the literature. (See. e.g., O’Shannessy et al.. J.

provides for the site speci?c photoinsertion of desired mol

reported to produce diagnostically and therapeutically prom

ecules to antibodies. It is further a speci?c object of the
invention to characterize the effects of these a?inity sites on

ising antibodies which are currently in clinical evaluation.

antibody function.

i'mmun. Meth., 99. 153-161 (1987)). This approach has been

65
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It is a more speci?c object of this invention to identify a

labeled antibody, in particular a labeled purine or purine
derivative containing compound labeled antibody. and more
particularly a labeled ATP- or GTP-analog photoa?inity

site or sites on antibodies having high a?inity for purines,

azido-purines and other similar heterocyclic organic
compounds, in particular ATP- or GTP-analog photoa?inity

compound antibody.

compounds.

It is another object of the invention to provide improved

immunotherapeutics, wherein such irnmunotherapeutics

It is another speci?c object of the invention to provide

comprise an antibody conjugated or complexed to molecules

methods for coupling desired molecules. e.g., e?’ector or

having therapeutic or cytotoxic activity, wherein the
improvement comprises using as the irnmunoconjugate an

reporter molecules to an antibody by site-speci?c attachment
of the molecules to nucleotide a?inity site or sites contained
on the antibody molecule or by attachment of the molecules
to a nucleotide photoat?nity compound which has been

10

a nucleotide or nucleoside a?inity site on the antibody. In the

photoinserted at said nucleotide a?inity site.

preferred embodiment, the a?inity site will have high a?inity

It is a more speci?c object of the invention to provide

methods for site-speci?cally photoai?nity coupling a purine.
azidopurine or similar heterocyclic base containing
compound. in particular an ATP- GTP-analog photoa?inity

15

compound. which compound is attached to one or more
molecules having a desired activity, to a site or sites con

It is another object of the invention to provide test lrits for
20

preferably an ATP- or GTP-analog photoa?inity compound.

25

kits for detection of antigens comprising diagnostically
eifective mounts of one or more of the following: antibodies.

a purine, azidopurine and/or a similar heterocyclic base

containing photoa?inity probe. reporter, any substrates nec

reporter or effector moieties wherein such ligands are

attached to the antibody at a site having high a?inity for

purine, azidopurine and other similar heterocyclic bases, in
35

nucleotide photoat?nity compounds before or after such

nucleotide photoa?inity probes to a nucleotide a?inity site or

nucleotide photoai?nity compounds are attached to a nucle
otide a?inity site or sites contained in an antibody molecule.

sites contained on the irnmunoglobulin molecule. It is a
more speci?c object of the invention to provide a method for

Other suitable heavy metals for photoattachment include.

photoa?inity labeling of antibodies by the attachment of a
labeled purine, azidopurine or other similar heterocyclic
base containing photoa?inity probe, and in partiurlar an

e.g., mercury and iron. In the preferred embodiment. the

nucleotide photoaf?nity compound will comprise a purine.
azidopurine and/or a similar heterocyclic base containing
compound. and most preferably will comprise ATP- or

ATP- or GTP-analog photoa?inity labeled compound to a
site or sites on the antibody having high a?inity of purine,
azidopurine and/or similar heterocyclic bases, and in par
ticular A'I'P- or G'I’P-analog photoat?nity compounds.
It is another objeat of the invention to provide photoaf

GTP-analog photoa?inity compounds.
It is yet another speci?c object of the invention to provide
a novel method of attaching nucleic acids to antibodies. e.g..

antisense nucleic acids, DNA, RNA or mixtures thereof,
50

wherein such antibodies have been coupled to a nucleotide
photoa?inity probe via a nucleotide a?‘inity site contained on

the antibody molecule.

comprising attaching said nucleic acids to the antibody
molecule using a nucleotide a?inity compound. preferably a
purine, azidopurine or similar heterocyclic base containing
nucleotide ai?nity compound, more particularly an AI'P- or

It is a more speci?c object of the invention to provide

photoa?inity labeled antibodies and compositions

essary for the detection of the reporter and diagnostic
carriers. wherein the various moieties may be separate or
may be in various forms of attachment.
It is yet another speci?c object of the invention to attach
heavy metals to antibodies which may or may not be

radioactive, in particular, ttiphosphate chelated heavy metals
such as 111In:“by reacting said chelated heavy metals with

for photoa?inity labeling of antibodies by the attachment of

?nity labeled antibodies and compositions containing,

from one another or may be in various forms of attachment.

It is a more specific object of the invention to provide test

speci?cally attached to the antibody via a nucleotide a?inity
site. or to a nucleotide photoa?inity analog attached to said
site.
It is a more speci?c object of the invention to provide
antibodies conjugated to desired molecules. in particular,

particular ATP- or GTP-analog photoa?inity compounds, or

otide photoa?‘inity probe. preferably an ATP- or GTP-analog

for the detection of the particular reporter. and diagnostic
carriers. and wherein the various moieties may be separate

It is another object of the invention to provide antibodies
conjugated to desired molecules, in particular. etfector or

to a nucleotide photoa?inity compound attached to said site.
It is another object of the invention to provide a method

mounts of one or more of the following: antibodies. nucle

photoa?inity compound. reporter. any substrate(s) necessary

which as been photoinserted onto said site or sites.

reporter molecules wherein such molecules are site

for purine derivatives. in particular ATP- or GTP-analog
photoa?inity compounds. The present invention further pro
vides methods of using said irnmunotherapeutics to treat
various disease conditions, and as imaging agents.

detection of antigens comprising diagnostically e?’ective

tained on the antibody molecule having high a?inity for
purine. azidopurine or other similar heterocyclic bases, or to

antibody which comprises one or more therapeutic or cyto

toxic molecules site-speci?cally attached to the antibody via

55

containing, wherein such antibodies have been coupled to a

GTP-analog photoa?inity compound which comprises a
highly negatively charged phosphate (tri or tetraphosphate)

having high at?nity for positively charged polylysine.

labeled purine, azidopurine and/or similar heterocyclic base
containing photoa?inity probe, in particular a labeled ATP

It is a more speci?c object of the invention to attach
desired molecules. e.g., reporter. or effector molecules

or GTP-analog photoaf?nity compound, at a site or sites on

which contain one or more reactive amino groups. or which
have been attached to a spacer comprising one or more

the antibodies having high a?inity for purine, azidopurine
and/or heterocyclic bases.

reactive amino groups, to an antibody by reacting same with

It is another object of the invention to provide improved

a nucleotide a?inity compound having a reactive cis-hydroyl

methods of immunodetection of an antigen. wherein such

group containing n'bose moiety, which cis-hydroyl group
may be convened to a dialdehyde under gentle conditions.

methods include the detection and/or quanti?cation of

antigen-antibody complexes using a labeled antibody
wherein the improvement comprises using as the labeled
antibody a nucleotide or nucleoside photoa?inity compound

65

and wherein such attachment may be etfected before or after

the nucleotide a?nity probe is attached to an antibody via
nucleotide a?inity site or sites contained on the antibody.

5,693,764
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BRIEF DESCRIPTION OF THE FIGURES

which provide for the selective site-speci?c attachment of
photoa?nity compounds thereto. In particular. it has been

FIG. 1 is a graph which compares the photoincorporation

discovered that antibodies comprise one or more sites hav

of ['fZP]-8-N3A'I'P into the heavy and light chains of the
SIC5 monoclonal antibody wherein the extent of photoin

ing high af?nity for purines. azido-purines and other similar
heterocyclic organic compounds. and speci?cally ATP- or

corporation is quanti?ed by liquid scintillation counting.

GTP-analogs. However, the present inventors do not wish to
be limited to purine or azidopurine binding sites. since,

The results show that the radioactive probe covalently
attached to both heavy and light chains.
FIG. 2 is a graph which compares the photoincorporation

of HJZPB-NBATP into the heavy and light chain sof the
SIC5 monoclonal antibody in the presence of increasing
quantities of ATP wherein photoincorporation is quanti?ed
by liquid scintillation counting. The results indicate that

given the teachings in this application. other photoa?inity
binding sites may further be identi?ed, e.g.. by reaction of
10

5'-triphosphate (5 -N3dUTP).
The purine or azidopurine nucleotide a?inity site will
hereinafter be referred to as the “purine ring binding” or
simply the “PRB" domain or site.
The PRB site on antibody molecules was discovered after

bition of photoincorporau'on of [ 2P]-8-N3ATP into the
SIC5 monoclonal antibody by oligonucleotides of different

it was found by the present inventors that photoa?inity

lengths. Le. a 2A-mer. a 30-mer. a 33-mer and a 58-mer,

wherein photoincorporation is again determined by liquid
20

compounds. in particular purine or azidopurine photoa?inity
compounds readily attach to antibodies and antibody frag
ments by a photoactivated chemical reaction which occurs

much greater inhibition with larger oligonucleotides.

under mild. physiological conditions. Speci?cally, it has

FIG. 4 is a graph of the results of a solid phase binding
assay [ELISA] which compares the ability of different
amounts of unlabeled 3H1 monoclonal antibody (ranging
from 0 to 10 M) to inhibit binding of the same amount of

compounds. e. g., pyrimidine derivatives such as photoactive

analogs of dUTP. including 5-azido-2'-deoxyuridine

50% inhibition occurs at about 350 |.|M.
FIG. 3 is a bar graph which co ares the percent inhi

scintillation counting. The bar graph shows that there is

antibodies with non-purine containing photoa?inity

been discovered that antibodies comprise one or more PRB

sites which exhibit such a high a?inity for purines and
25

azidopurine photoa?inity analogs, that reaction of antibodies
with purine and azidopurine photoa?inity analogs under

[f2P]-8-N3ATP labeled 3H1 monoclonal antibody to the
corresponding idiotypic antibody, and wherein the SD10

mild. physiological conditions. and more particularly after

antibody is used as a non-speci?c cold (unlabeled) inhibitor.

photoattachment.

only a single 2-5 minute photolysis results in nearly 100%

Photoincorporation is again quanti?ed by liquid scintillation
counting. The results show that cold (unlabeled) 3H1 mono

30

clonal antibody inhibits binding of the labeled 3H1 antibody.
FIG. 5 is a bar graph which compares the ability of
different amounts of unlabeled SD10 monoclonal antibody
(5.0. 1.0. 0.5 pg) to inhibit binding of the same amount of
[Y'QPLS-NSATP labeled 5D 10 monoclonal antibody to live
DHIA- human lymphoma tumor cells.
FIG. 6 is a photograph of the isoelectric focussing pattern
of unlabeled and ["{32P]-8-N3ATP labeled SIC5 monoclonal

bodies. Thus. the present invention provides an improved
35

However, it should be emphasized that while the condi
tions which facilitate the attachment of nucleotide photoaf
?nity compounds to antibodies are inherently gentle. this, in
itself. did not ensure a successful outcome. Foremost, prior

to the invention, it could not have been predicted with any

B=equine myoglobin (pI 7.0). C=bovine carbonic anhydrase
(pI 6.0). D=phycocyanin (pI 4.65) (lane 10). The unlabeled

degree of certainty that this photoa?inity reaction would
occur under any conditions. because it was not known that
45

antibodies comprise site or sites having a?inity for photo
ai?nity compounds. in particular nucleotide and nucleoside
photoai?nity compounds. and more particularly sites having
high ai?nity for purine. azidopurine or similar heterocyclic
base containing photoa?inity compounds. Moreover, even

50

assuming that the existence such sites had been known. it
could not have been predicted that reaction with such sites

100 pM (lane 4). 200 pM (lane 3), 400 pM (lane 2).
FIG. 7 is a photograph of an autoradiograph made from an
SDS-PAGE on which different antibodies which had been

photolabeled with ['y“P]-8-N3ATP were separated. In
particular. autoradiograph shows separation of a murine

monoclonal IgGl antibody. SD10 monoclonal antibody

(lane 1), murine myeloma IgGl (lane 2). murine myeloma
IgA (lane 3), goat Ig (lane 4), goat (Fab)2 fragments (lane 5),
human myeloma IgGlK (lane 6), human myeloma IgGl

method for the attachment of desired molecules to
antibodies. since it utilizes reaction conditions which are

more compatible with the preservation of labile biological
molecules and living cells.

antibody. wherein the SIC5 antibody is photolabeled using
increasing concentrations of [f2P]-8-N3ATP. The isoelec
tric focussing standards are A=cytochrome C(pI 9.6),
SIC5 antibody is in lane 1. The [f2P]-8-N3AI'P labelled
SIC5 antibody are as follows: 3.25 M (lane 9), 6.25 |.|M
(lane 8). 12.5 pin (lane 7). 25|JM (lane 6). 50M (lane 5).

This is in contrast to the harsh and potentially damaging
conditions which are generally required to facilitate the
elfective covalent attachment of desired molecules to anti

55

with compatible photoa?inity compounds would not have
adversely affected antibody activity. most especially the
ability of the antibody to bind antigen. For example. it was
entirely possible that the nucleotide or nucleoside photoaf
?nity compounds could have inserted in the antibody mol

(lane 7). human myeloma IgM (lane 8). murine monoclonal
IgM (lane 9) and murine monoclonal IgG2b. SIC5 (lane 10)

ecule at a site or sites within or su?iciently proximate to the

which had photolyzed in the presence of 200 pM {Wm-s
NsATP and were separated by 55-16% gradient SDS-PAGE,
stained with Coomassive Blue. dried and autoradiographed.

was lost or substantially impaired. Alternatively, it was
possible that the insertion of the nucleotide or nucleoside

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS OF THE

have induced conformational changes in the antibody mol
ecule causing substantial reduction or loss of other antibody
functions. However. quite surprisingly it has been found that

INVENTION

The present invention provides the discovery that some. if
not all. antibodies contain one or more photoa?inity sites

antigen combining site. such that antigen binding activity
photoa?inity compounds into anu'body molecules could

65

nucleotide photoat?nity analogs readily attach to antibodies.
in a site-specific manner. under conditions which do not

result in substantial loss of antigen binding activity.

5,693,764
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invention will preferably comprise adenine analogs.

Thus, the invention in general provides a novel means for

site-speci?cally photoattaching desired molecules to anti

although guanine analogs can be substituted therefor. For

bodies nucleotide or nucleoside a?inity sites contained in the

example, purine binding sites may be effectively labeled by

antibody. The invention further provides general methods

the following, and their 5'-mono-. di- and triphosphates:
oligomers of a single azidoadenylyl species. such as, for
example: 2~azido or 2-azidoadenylyl(2'-5‘)2-azidoadenylyl
(2'-5')2-azidoadenosine; 2-azido or ?-azidoadadenosine;

for studying the function of these nucleotide and nucleoside

a?inity sites, by binding di?erent nucleotide and nucleoside
photoat‘?nity compounds to these sites and evaluating their
effects on antibody functions, e. g., effector functions.
As discussed in the Background of the Invention. methods

for photoinsertion of nucleotide photoa?inity compounds,
and speci?cally purine and purine analog photoal?nity com
pounds in proteins having speci?c nucleotide binding sites

8-azidoadenylyl(2'-5')-8-azidoadenylyl(2'-5’)8

azidoadenosine; 8-azidoadenylyl(2‘-5')- 8-azidoadenylyl(2'
10

diazidoadenylyl(2'-5‘)2,8-diazidoadenylyl(2‘-5’)2.8-diazido
adenosine; 2.8-diazidoadenylyl(2'-5')2.8-diazidoadenylyl

have been reported in the literature. The subject invention
embraces any set of reaction conditions which provides for
the effective photoinsertion of a nucleotide or nucleoside

photoa?inity compound, preferably a ptn’ine, azidopurine or

(2‘-5')-2.8-diazidoadenylyl(2’-5')2,S-diazidoadenosine; also
15

oligomers containing more than one azidoadenylyl species.
such as, for example: 2-azidoadenylyl(2'-5')S-azidoadenylyl
(2'-5')2-azidoadenosine; also oligomers resulting from any

and most preferably an ATP- or GTP-analog photoa?inity
compound, into an antibody molecule, which does not result

combination of the monomers AMP. 2-azido-AMP, 8-azido
AMP and/or 2,8-diazido-AMP. provided that at least one
such monomer incorporated into the oligomer is an azido

25
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Alternatively, guanine moieties can be de?ned in each of

the exemplary compounds in place of the respective adenine
moieties. Therefore, certain most preferred compounds of
the present invention are synthesized from azidoguanosine

e?’ectively binds nucleotide or nucleoside photoa?nity com

antibodies, recombinant antibodies, chimeric antibodies,
bispeci?c antibodies, single chain antibodies, antibodies
from di?’erent species (e.g., mouse, goat, rabbit, human, rat,
bovine, etc), anti-idiotypic antibodies, antibodies of differ
ent isotype (IgG, IgM, IgE. IgA. etc.), as well as fragments

AMP species.
In addition photoa?inity compounds of the invention may
also include photoactive coenzyme analogs of NAD", exem
pli?ed by nicotinamide Z-azidoadenosine dinucleotide
(2-azido-NAD+), or analogs of NADH. exempli?ed by

nicotinamide Z-hydrazidoadenosine dinucleotide (2-azido
NADH).

Any antibody or antibody containing composition which
pounds is within the scope of the present invention. This
includes by way of example, polyclonal and monoclonal

oligomers of AMP and a single azidoadenylyl species. such
as. for example: 2-azidoadenylyl(2'-S')2-(2'-5‘)adenosine;

adenylyl(2'-5')8-azido adenyl(2’-5‘)8-azidoadenosine; also

similar heterocyclic base containing photoaf?nity analog.
in substantial loss of antigen binding.
Suitable methods for attaching nucleotide photoa?inity
analogs to proteins are described. e.g., in Potter & Haley,
Meth. in EnzymoL, 91:613-633, (1983); Owens & Haley, J.
Biol. Chem., 259: 14843-148 48, (1987);Atherton et al. Biol.
of Reprvd, 32:155-171. (1985); Khatoon et al, Ann. of
Neurology, 26:210-219, (1989); King et al, J. Biol. Chem,
269210210-10218, (1989); Dholakia et al, J. Biol. Chem.,
264220638-20642. (1989); Campbell et al, Proc. Natl. Acad.
Sci, 87:1243-1246, (1990); and Kim et al, J. Biol. Chem,
265:3636-3641, (1990), which references are incorporated
by reference in their entirety herein.

5')8-azidoadenylyl-(2'-5')8-azidoadenosine; 2.8

35

5'-triphosphates or combinations thereof, or from azidogua
nosine 5'-triphosphates and ATP. The latter provides a (2’

5')oligomer containing both guanylyl and azidoguanylyl
moieties.

Furthermore, photoa?inity compounds of the present
invention may also include, for example, pyrimidine deriva

and derivatives thereof. (e.g., (Fab)2 fragments.)

tives. For instance, photoactive analogs of dUTP, such as

Optimal reaction conditions will vary dependent upon

5-azido-2'-deoxyuridine 5’-triphosphate (5-N3dUTP), may

factors including the concentration of antibodies in the

be synthesized from dUMP and provide a pathway for the
synthesis of other useful S-subs?tnted uridine nucleotides.

particular composition, the isotype and/or species origin of
such antibodies, and the number and at?nity of nucleotide or
nucleoside binding sites present on the particular antibodies.
Suitable conditions can readily be determined by the skilled

45

polymerizing enzymes to generate additional photoactive
nucleic acids which remain stable to extremes of pH and

artisan by reference to the above-cited publications relating
to nucleotide photoa?inity labeling of proteins, and the

examples therein.

50

The invention further embraces the use of any nucleotide

which remain effective photolabeling reagents in the pres
ence of reducing agents. Moreover. since the synthesis of
5-N3dUTP employs mild conditions, it is also possible to

synthesize homopolymers of 5-N3dUTP to provide single
stranded photoactive DNA of de?ned length. Using 5N3UTP

or nucleoside photoa?inity compounds which e?ectively
photoinserts into one or more nucleotide a?inity sites of a

selected antibody under conditions which provide for the

substantial retention of antigen binding activity. Moreover,

The 5—diazouridine nucleotides may, for example. serve as
active-site-directed photoa?inity probes or as substrates for

55

if the antibody is to be used as a therapeutic agent, such

conditions should preferably preserve other antibody
functions. e.g.. etfector functions, comprised in the Fc
portion of the antibody molecule (e. g., complement

one can similarly produce photoactive RNA.
Generalized methods for the synthesis of aryl azides
include nucleophilic displacement of a bromine, chlorine or
nine group by an azide ion or the addition of sodium azide
to an acidic solution containing a diazotized primary aro

matic amine.

activation).
The particular nucleotide or nucleoside photoa?inity
compound may be directly reacted with an antibody, or it

To date the most widely used 8-azidopurine is probably
8N3cAMP. One of the advantages of 8N3cAMP is that in
mammalian systems there are only two types of proteins that

may ?rst be attached to another compound, e.g., a molecule
having a desired elfector function or a reporter molecule,

phosphodiesterases and the regulatory subunits of the

are known to bind cAMP with high a?inity. the cAMP

Many nucleotide photoa?inity probes may be synthesized

cAMP-dependent protein kinases. The photoprobes [32F]
8N3cAMP and [32P]8N3ATP have been employed to study,

and used successfully. The photoafinity compounds of the

for example, the mechanisms of action of cAMP-dependent

e.g., a radioactive label.

65
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protein kinase. Photoactive analogs of GTP. e.g.. P2P]
SNBGTP. have been developed to study. for example, tubulin
polymerization. while photoactive analogs of UTP. e.g..
[32P]5N3dUTP have been generated to study, for example,
the binding site of DNA binding proteins.

hybridization). Solution hybridization is preferred in the
present method. Another method of interest is the sandwich

hybridization technique.
Certain factors are considered when a unique biochemical
macromolecular marker is identi?ed by means of a radio

Preferred compounds of the present invention are synthe
sized from azidoadenosine 5'-triphosphates or combinations

active photoa?inity label. as is the preferred method of the
present invention. For example. consideration should be
given to: (a) temperature of incubation and photolysis. (b)
length of incubation and photolysis. (c) concentration of

thereof. which provide a (2'-5‘)oligomer containing both

adenylyl and azidoadenylyl moleties. Especially preferred
photoa?inity compounds for use in the present invention
include in particular Z-aZido-ATP. 8-azido-ATP and

10

benzophcnone-A'I'P or other compounds which e?ectively
compete with 2 or 8-azido-ATP for occupancy of the PRB

binding domain.

unused label. and (i) interpretation of results. Potter & Haley
in Meth. in Enzymol. 91:613-633 (1983) provide a detailed
account of preferred procedures for labeling a speci?c

As noted. these photoa?inity compounds may further be
attached to other molecules. e.g.. effector molecules or

reporter molecules. provided that such molecules do not

adversely a?’ect the ability of the photoa?inity compound to
effectively photoinsert into nucleotide binding site or sites
contained in the particular antibody. or provided that such

biochemical marker macromolecule in a sample with a

photosensitive pln-ine triphosphate azide analog.
20

molecules may be effectively attached to a nucleotide or

nucleoside photoa?inity compound which has been bound to

the particular antibody.

from 8 to 40 carbon atoms. preferably from 9 to 30 carbon
atoms. The dyes further normally contain from 1 to 10
heteroatoms usually oxygen. nitrogen. or sulfur. and nor
mally contain no halogen atoms or up to 10 halogen atoms

25
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isothiocyanate. tetramethylrhodarnine isothiocyanate. and

temperature. and photolysis in plates set on ice to reduce the

incubated at room temperature with the radioactive photo
a?inity probe for approximately 0.5 to 1.0 minutes. Most
preferably the mixture is vortexed for 6 seconds followed by
an additional 24 seconds of mixing. immediately followed

by placing the sample on ice for photoactivation.

4-acetamido4-isothiocyanostilbene-Z with 2‘-disul.fonic

The concentration of photoa?inity reagent must be com

acid. Fluorescent purine derivatives may also include, for

patible with the binding a?inity of the antibody which is to
be labeled. Excessively high concentrations. however. can
lead to undesirable nonspeci?c labeling which increases
linearly with concentration. Best results can be obtained by

example. the ?uorescent GTP analog 2'3'-O-(2.4.6

trinitrocyclohexadienylo-idine)guanosine 5'-triphosphate
('l‘N'P~GTP). or the equivalent ?uorescent ATP derivative

('I‘NP-A'I‘P).
Chemiluminescent dyes may include 5-amino-2.3
dihydro-phthalazine-l.4-dione (lurninol). derivatives of iso

8-N3cAMP is bound to the speci?c macromolecular marker.
it may be cold trapped onto the protein by dropping the
temperature to nearly 0'’ C. Therefore. the most preferred
procedure includes preincubation of the components at room

invention. the antibody containing sample is preferably

Chromogenic dyes may include phenol sulfonephthalein
and analogs of tetrazolium.

dichlorotriazinylamino ?uorescein. morpholinorhodamine

8-N3cAMP approaches negligible levels at 0° C.. and is
greatly increased at room temperature. Conversely. once

temperature to approximately 0° to 4° C. By the present

usually iodine. bromine. chlorine. or ?uorine.

Fluorogenic dyes may include ?uorescein isothiocyanate.

Temperature of the photolysis reaction between the anti
body sample and the selected photoaf?nity label can range
from 0° C. to room temperature (25° C.) or above. However.
the exchange rate between bound and unbound cAMP or

Nonradioactive reporter molecules or labels can be

divided into two categories: (i) chromogenic. ?uorogenic. or
chemiluminescent dyes or (ii) ligands. Dyes are normally of

photoa?inity reagent. (d) binding affinity of protein for the
reagent and natural ligands. (e) stability of the photoa?inity
reagent in each particular system. (i) ionic strength. pH.
cofactors. (g) protein concentration. (h) intensity of photo
lyzing light. (i) quenching of reaction and separation of

experimentally determining the optimum concentran'on for
45

lurninol and acridinium esters.

photoincorporation. Directly related to the determination of
concentration is the stability of the reagent. The stability of
the reagent can be determined by thin-layer

Any ligand may be employed for which an appropriate
receptor may be found to have satisfactory speci?city for the

chromatography. e.g.. by ?uorescent cellulose thin-layer

chromatography.

ligand. For example. the subject labeling method provides
for the e?icient attachment of biotin to antibodies using the

Ionic strength, pH. oofactor. and metal ion concentrations

subject nucleotide or nucleoside photoaf?nity compounds.
Speci?cally. this has been demonstrated by Western Blot
(testing for reaction with avidin) using azido-ATP and

can each a?ect antibody structure. and are readily adjusted
by those skilled in the art to achieve optimal labeling

azido—GTP compounds.
Various methods or protocols may be employed in mea
suring the amount of the labels. These protocols can include

$5

time. decreasing the rate of photoincorporation. Aggregation
of the protein can also affect the binding time of the reagent

for example. radioimmunoassay (RIA). immunoradiometric
assay (IRMA). sandwich IRMA. ?uoroimmunoassay (FIA).

to the protein. thereby increasing or decreasing photoincor
poration. One must experimentally redeterrnine optimal
photolysis time when changing protein concentration if
maximum incorporation of the photolabel is desired.

chemiluminescent assays. bioluminescent assays, and
enzyme linked irmnunosorbent assays (ELISA) among oth
ers.

Detection of the labeled antibody occurs following an
appropriate. predetermined incubation time to e?‘ect a
reaction. and is calculated on the basis of the antibody

The labeled probe of the present invention can be used in

any conventional hybridization technique. Hybridization
formats which may be useful in the practice of the present
invention include those in which the sample is immobilized
on a solid support (solid-phase hybridization) and those
wherein the species are all in solution (solution

conditions. The higher the protein content of the sample. the
denser the solution becomes to light. Therefore. in a denser
solution. less UV light reaches the photoreagent per unit of

65

sample and the selected photoa?inity probe.
The intensity of the photolyzing light is such that maxi
mum photoincorporation can be obtained in a minimum

5,693,764
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amount of time without appreciable change in temperature

phosphotransfer from the triphosphate derivative N3ATP or

or damage to the biological sample. Preferably the photoly

NSGTP may be inhibited by chelators such as EDTA. The

sis is achieved at 254 nm with an ultraviolet light source.

preferred protein solubilizing agent is a detergent. particu

Ultraviolet (UV) light is essential for the activation of the
photoprobe treated samples. but only a low intensity UV
light is necessary. The intensity of the UV light can range
from 180 to 800 nW/cm2 by conventional sources to 4000
nW/cm2 and above when a high intensity source is used to

(PSM). such as described by Potter & Haley in Meth. in
EnzymoL, 91:613-633 (1983) or by procedures standard to

larly SDS. most preferably in a protein solubilizing mix

most published procedures. A particularly preferred concen
tration of SDS in the mix is 10%, resulting in a concentration
of SDS to the ?nal sample of 4 %.

achieve rapid photolysis.
Photolysis times range from 15 seconds to 5 minutes and
must be experimentally determined for each reaction sys

tem. For lamps having intensi?es of 180-800 pW/cm“, the
preferred photolysis time ranges from approximately 30 to
120 seconds, most preferably, photolysis is effected in
approximately 30 to 60 seconds.
The distance of the light source from the sample is a
determinative factor in the conditions of photolysis. A pre
ferred method of the present invention uses an ultraviolet

Solubilization can occur either at 0° C. or at higher

temperatures without atfecting the results. However. solu
bilization in the present invention is effective at room

temperature.
15

?lter paper, starch gels or blocks, cellulose or polyurethane

light source having su?icient intensity. about 6200 pwlcmz.

foam. Any effective. known method of protein separation
may be used, but preferably separation is by electrophoresis

positioned at a set distance, about 1 cm from the sample, for

a time su?icient to e?’ect photoactivation. generally approxi
mately 45 seconds.
The labeled macromolecule is typically separated from

over denaturing or nondenaturing gels, or over a gradient of

either type. In the present method, protein separation is
usually by electrophoresis on a denaturing gel.

the solution containing excess unbound sample and/or label

by precipitation, although other recognized methods of
protein puri?cation are possible. Recognized methods of

25

precipitation include. but are not limited to addition of an

effective protein precipitating agent such as trichloroacetic

acid (TCA). perchloric acid (PCA), acetone, ammonium
sulfate polyethylene-glycol (PEG) or the like to the sample.
PCA or ammonium sulfate are the preferred precipitating

30

agents in the present method. and PCA is the particularly

35

solution. The most preferred concentration of the precipi

tating agent is that mount which effectively precipitates the

or by isoelectric focusing (IEF) or on two dimensional

initial voltage of about 140 volts. Any standard electro
phoresis equipment can be utilized.
The resultant gels are exposed to X-ray ?lm and visual
ized by autoradiography according to methods well known

presence of the unique speci?c protein band or to ascertain
that differences in the amount of photolabel incorporation
are not due to drastic changes in the protein levels. Many
known protein staining methods are widely recognized. e.g..

The precipitating agent can be mixed with the sample as
a dry batch addition or in a calculated equivalent liquid
form. The required mixing time may vary with the nature of
the agent selected and the size or concentration of the

the precipitated protein from the solution is by centrifuga

achieve protein separation. The protein fractions of the
present invention most preferably may be separated by
electrophoresis on an SDS-polyacrylamide gel (SDS-PAGE)

in the art. The gels can also be stained to determine the

previously activated, photolabeled antibody sample.

essentially no additional protein is precipitated from the
sample solution at the temperature selected.
The precipitated antibodies may be separated from solu
tion by any e?’ective means, such as centrifugation. sedi
mentation or ?ltration. A preferred method of separation of

the gel used, which in turn determines the time for separa
tion and the electrical current which must be applied to best

tionated on a 10% polyacrylamide gel. run over a period of
2V: to 3 hours, with constant amperage of 35 mA and an

which effectively precipitates the speci?c antibody from

sample. However, the time required is that point after which

The nature of the sample and the size of the speci?c
nucleotide binding protein determine the concentration of

systems (IEFxSDS-PAGE). Typically. the sample is frac

preferred precipitating agent.
The amount of precipitating agent is determined by the
concentration of protein in the sample. The preferred con
centration of the precipitating agent is that concentration

Upon solubilization, the protein sample is applied to a
suitable support for separation of the protein fractions.
Support materials could include. e.g., polyacrylamide gels,

45

Coomassie Brilliant Blue (CBB) or silver staining. CBB is
a commonly used stain that detects proteins based on a

hydrophobic interaction between the proteins and the dye.
Although any available staining method can be used which

effectively distinguishes the speci?c nucleotide binding
protein, CBB is the fastest and most economical for the
50

present method.

Most preferably, each completed SDS-PAGE gel is

tion at a su?icient speed and for a su?icient time to e?ec

stained with an effective amount of CR8 to stain the selected

tively isolate the antibody proteins into a pellet. for example
by centrifugation. However. the parameters vary with the

protein fragments. However. many times proteins can be
detected by photolabelling that cannot be detected by any

nature of the antibody solution.
To determine the effectiveness of the precipitation and

protein staining procedure. In particular, the completed gel
is immersed in a 10% CBB (wlv) solution for about 1 hour.
Then the gel is destained in a solution to effectively remove
excess stain. Particularly preferred is a destaining solution of

separation procedures. both the pellet and the supernatant
?uid are analyzed for protein content.
The precipitated protein may be solubilized and any

5% acetic acid and 10% isopropyl alcohol applied for 10-18

remaining reaction quenched by any etfective, lmown

hours.

method. The determination of the solubilizing agent would

Finally, the speci?c binding protein fragments may be
visualized by standard autoradiography techniques. The use

depend on the ultimate method of identifying the speci?c
nucleotide binding protein. Therefore, such agents could
include, e.g., sodium dodecyl sulfate (SDS) or urea, and
certain stabilizing agents.

Any azide remaining after photolysis may be destroyed by
the addition of dithiothreitol or its equivalent, and potential

of an intensifying screen effectively accelerates the visual
65

ization process of autoradiography. By the method of the
present invention, the stained gel is dried. and then exposed
to DuPont Cronex 4 X-ray ?lm. The autoradiographic pro
cedure is for variable time periods depending on the speci?c

5,693,764
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activity of the probe photoinserted into the proteins of each
experimental sample. Alternately. if maintained at —70° C.,
the gel can be subjected to autoradiographic procedures

suberate. aldehydes such as glutaraldehyde, bis-azido
compounds, bis-diazonium derivatives such as bis-(p
diazonium benzoylyethylenediamine, diisocynates such as
tolylene 2.6-diisocyanate, and bis-active ?uorine com

while still in the gel state.
The amount of protein, as well as the radioactivity incor

pounds such as 1,5 -di?uoro-2,4 -ditrobenzene.
Particular types of effector molecules considered to have

porated into each protein, can be quanti?ed by known

preferred application in the invention include radiolabels
and chelating agents, in
'cular triphosphate chelated

methods including, but not limited to, densitometric scans of

the exposed X-ray ?lm, or of the stained gel, or by liquid
scintillation spectrometry of the protein band following
excision from the gel.
As discussed supra, another application of the subject

heavy metals such as 111In + (which has known application
10

a?inity labeling method comprises the attachment of desired
effector molecules to antibodies, wherein these molecules
are site-speci?cally attached to a photoa?inity site, in par
ticular at a site or sites having high a?inity for purine.
azidopurine and other similar heterocyclic bases, and more

as a diagnostic imaging agent), nucleic acids having utility
in gene therapy or antisense therapy, enzymes having diag
nostic or therapeutic utility, and toxins.
Effector molecules may be attached to the photoa?inity
compound. preferably a purine or azidopurine photoa?inity
compound and more preferably an AI'P- or GTP-analog

photoa?inity compound, by various means of attachment
The selection of suitable means of attachment will depend
upon the particular effector and functional groups available
for covalent attachment or complexation to the particular

particularly ATP- or GTP-analog photoa?inity compounds.
This is an important application of the subject method given
that the present method of attachment is site-speci?c and
does not substantially affect the architecture of the antibody
molecule or its ability to bind antigen. Therefore. effector

nucleotide or nucleoside photoa?inity compound.
Preferably, such chemical attachment will occur under mild

molecule containing antibodies produced by this method

conditions to preserve the activity of the antibody and

will bind to a target more effectively, e.g., a tumor cell

effector.

expressing the corresponding antigen Moreover, non
speci?c binding should be minimized which is highly sig

For example, proteins may be attached to the subject
25

and more particularly AI'P- and GTP-analog photoa?inity
compounds, by converting the cis-hydroyl group on the

ni?cant if the antibody-effector conjugate is to be used as a

therapeutic agent, since this should minimize systemic tox

icity.
The subject method is applicable for site-speci?cally
attaching any eifector molecule which, when attached to a

30

nucleotide photoaf?nity compound does not adversely atfect
the ability of the resultant effector-nucleotide photoa?inity
compound to site-speci?cally attach to a nucleic acid bind

ing site comprised on the antibody molecule. or which may
be site-speci?cally attached to a nucleotide photoa?inity

35

compound which has been previously been site-speci?cally
bound to a nucleic acid binding site on an antibody.

As noted previously, an e?iector molecule is broadly
de?ned as any moiety which comprises a desired functions,
e.g., a particular biological or chemical activity. In the

tetraphosphate. Consequently, this will permit established
procedures to be used to couple a polylysine containing
polynucleotide. e.g., DNA, RNA or complexes thereof, to
the photolabeled antibody. This will further enable the
polynucleotide to be site-speci?cally targeted to an antigen

lar 111Ina", wherein this reaction may be e?‘edzed before or
45

Examples of effector molecules within the scope of the

after the photoa?inity compound is attached to the antibody.

Preferably, the photoa?inity compounds will comprise ATP
or GTP-analog photoa?inity compounds, and most prefer

invention include by way of example cytotoxic moteties
such as enzymatically active toxins and fragments thereof

such as diphtheria toxin, Pseudomonas exotoxin, ricin A.
50

ably Z-aZidO-AH‘P, 8-azido-ATP or benzophenone-ATP.
When used in vivo for therapy, the effector-antibody con
jugates of the invention will be administered in therapeuti
cally effective amounts. This will of course depend upon

factors including the specific disease condition being
treated, the condition of the patient, the antigen binding

PAPII. PAPII) , Mornardica charantia inhibitor, carcin,

erotin. Sapanaria o?icinalis inhibitor, gelonin, mitogellin.

properties of the antibody (a?inity, avidity of antibody for

restrictocin, phenomycin , and enomycin antitumor agents

such as daunomycin, daunorubicin, methotrexate, cytokines
such as interleukins (IL-l. lL-2, etc.). interferons (0t

proteins or other amino group containing compounds.
Also, the subject photolabeled antibodies have been
shown to have very high a?inity to polylysine because of the
presence of a highly negatively charged triphosphate or

Additionally, it has been shown that the subject nucleotide
photoai?nity compounds attach under gentle conditions to
heavy metals, e.g., triphosphate chelated metals, in particu

which enables the etfector-antibody conjugate to be used as
a therapeutic or an imaging agent, e.g., for treating or

abrin A, modeccin A. alpha-sarcin, Alevritesfoniii proteins,
dianthin proteins, Phytolacca americana proteins (PAPI,

ribose under gentle conditions to a dialdchyde. The dialde
hyde will then form a Schitf's base with amino groups of

expressing target, e.g., a tumor cell or a site of infection.

preferred embodiment, the e?‘ector will comprise an activity

visualizing tumors.

purine or purine derivative containing photoa?inity probes,

$5

antigen), and the particular effector molecule that is attached
to the antibody. Particular disease conditions contemplated
for treatment include, e.g., cancers, infectious diseases, and

interferon, B interferon, 'y interferon), colony stimulating

genetic disorders.

factors, tumor necrosis factors, and lymphotoxins, enzymes,

The subject photoa?inity compound antibody-conjugates

radionuclides, chelating agents, growth factors, polynucle

will normally be administered parenterally, when possible at

otides (DNA, RNA, antisense DNA or RNA mixtures
thereof) heavy metal isotopes, as well as other moieties

the target, e.g., a tumor, at particular organ, or a site of

having therapeutic or diagnostic utility.

infection.

The effector moieties may be directly attached to the
photoal?nity compound, or attachment may be effected

For parenteral administration these conjugates will be
formulated in a unit dosage injectable form (solution.
suspension, emulsion) in association with a pharmaceuti
cally acceptable parenteral vehicle. Such vehicles are inher

using a bifunctional coupling agent. Examples of such
reagents include by way of example SPDP, II‘, dimethyl
adipimidate HCl , active esters such as disuccinirnidyl

65

ently nontoxic. and non-therapeutic. Examples of such
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vehicles are water, saline. Ringer’s solution, dextrose
solution, and 5% human serum albumin. Nonaqueous
vehicles such as ?xed oils and ethyl oleate may also be used.
Liposomes may be used as carriers. The vehicle may contain

amounts of tree ATP. Speci?cally. 3 pg of the SIC5 antibody
was photolyzed in the presence of 200 pm ['y:‘2P]-8-N3 ATP
using concentrations of ATP ranging from 0 to 700 pm. The

minor amounts of additives such as substances that enhance

radioactivity determined by liquid scintillation counting.

isotonicity and chemical stability, e.g.. buifers and preser

These results are shown in FIG. 2.
Based on the results contained therein. it can be clearly

labeled protein was again separated by SDS-PAGE; and

vatives. The antibody conjugates will typically be formu
lated in such vehicles at concentrations of about 1 mg/ml to

seen that ATP inhibits labeling of both the heavy and light
antibody chains of the SIC5 antibody. The results further

10 mg/ml.
The selection of an antibody subclass for therapy will
depend upon the nature of the antigen. For example. an IgM
may be preferred in situations where the antigen is highly
speci?c for the target and rarely occurs on normal cells.
However. where the antigen is also expressed in non
targeted. e.g., normal tissues. an IgG antibody may be

indicate that 50 % of inhibition of labeling occurs at around
a 350 um ATP concentration. Thus. these results provide
further evidence that the SIC5 antibody comprises one or

more sites having speci?c a?inity for the lynPHi-N3 ATP

compound.
15

Example 3

preferred.

Labeling of the SIC5 Antibody Using {7”P1-8-N3
ATP Benzophenone
Another photoactivating probe. [32P]-8-N3 ATP

The following examples are o?ered to more further
illustrate the nature, but are not to be construed as limiting

the scope thereof.

benzophenone. was tested to determine its ei?cacy for

EXAMPLES

labeling the SIC5 antibody. This experiment was conducted

Standard procedures and reagents were used in accor

under substantially the same conditions as Example 1.

dance with Maniatis et al (1982) Molecular Cloning: A

Laboratory Manual. Cold Spring Harbor Laboratory, New
York. Speci?c techniques for the photoa?inity labeling of
speci?c nucleotide binding sites with purine phosphate azide

25

light chains were then measured. It was demonstrated that
saturation was achieved at about 100 mM concentration of

analogues were used in accordance with Potter & Haley.

probe.

Meth. in EnzymoL, 90:613-633 (1983).

These results indicate that the SIC5 antibody comprises
one or more a?inity sites which are eifectively labeled by the

Example 1

[y32P]-8-N3 ATP benzophenone compound. and that the
SIC5 antibody may be e?edively labeled using dill‘erent
nucleotide photoactivating probes.

Labeling Ef?ciency of [Wm-8+1. ATP for SIC5

Antibody
The SIC5 antibody comprises an anti-B cell lymphoma
idiotype antibody which is useful for evaluating the e?i

except that [\(32P]-8-N3 benzophenone was substituted for
[Y”P]-8-N3. Incorporation of label into the SIC5 heavy and

35

Example 4

ciency of labeling by idiotype solid phase assays and minor

A?‘inity of SIC5 Antibody Site for Oligonucleotides

cell binding as well as in tumor imaging. Therefore. given
these inherent properties. this antibody was selected to

The a?inity of the SIC5 antibody for oligonucleotides was
also evaluated using oligonucleotides of different length. to
block photolabeling with an ATP probe. Speci?cally. 3 pg of
the SIC5 antibody was incubated for two hours at 4° C. with
1 mg of a 24-mer. 30-mrn'. 33-mer. 58-mer. followed by
incubation with 200 pm of [Yi2P]-8-N3 ATP for 60 seconds.

determine labeling e?iciency of the subject method.
In particular. 3 pg of SIC5 antibody in 30 mL of pho
tolysis bu?er was photolyzed with increasing concentrations
of [732P]-8-N3 ATP and then separated by SDS-PAGE. 32P
incorporation was detected by autoradiography and quanti

?ed by scanning on Optical Imaging Acquisition Analysis

45

(Ambis. Inc.). Photoinoorporatiou was quantitatively con
?rmed by cutting the appropriate bond and determining
radioactivity by liquid scintillation counting. These results

mining 32F radioac?vity by liquid scintillation counting.
These results are contained in FIG. 3. Based on these results.

are set forth in FIG. 1. Based upon these results. it can be

it would appear that blocking e?iciency increases with the

clearly seen that the radioactive probe is covalently attach
ing to both antibody heavy and light chains. It can further be
seen that there is a de?ned saturating concentration of probe
at about 200 pm for both chains. This saturation plateau
provides strong evidence that there exists a unique and

50

limited number of a?inity sites of the antibody which are

SS

antibody having speci?c a?inity for ATP photoa?inity
probes. Additional experiments are planned using oligo
nucleotides of speci?c sequences to further analyze the

sequence speci?city of the a?inity site(s).

Example 5

Example 2

Effect of Labeling on Antigen Binding
The effect of labeling on antigen binding and antigen
speci?city was determined using the 3H1 anti-idiotype
antibody. for which an idiotype is readily available. The

Determination of the Speci?city of the Antibody
Nucleic Af?nity Site

In order to identify which pan of the [7”P1-8-N, ATP
probe is binding the antibody. i.e.. the speci?city of the
antibody a?inity site. the following experiment was con
The SIC5 antibody was again labeled. but in this example
labeling was performed in the presence of increasing

length of the oligonucleotide. This provides further evidence
in support of the existence of one or more sites on the

bound by the ["f‘zPHi-N3 ATP compound.

ducted

photolysis for 60 seconds, followed by separation of protein
using SDS-PAGE. Photoincorporation was again quantita
tively determined by cutting the appropriate band and deter

binding of 3H1 to idiotype was tested in a solid phase

binding assay (ELISA) using isotope labeled 3H1 in the
65

presence of unlabeled 3H1 antibody to inhibit binding.
In particular. the idiotype antibody was used as antigen for
plate coating (500 mglwell). The same mount of labeled 3H1

5,693,764
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(311g) was mixed with different mounts of the unlabeled
antibody and incubated for two hours at 25° C. After
incubation. the wells were washed. dried, out and 32F

The results indicate that these different antibodies effec

tively incorporate the label into the heavy and light chains
and that the amount of incorporation varies with the di?erent
antibodies. It can further be seen that a Fab fragment (goat

radioactively counted by liquid scintillation. The SD10

Ig is Fab fragment) is etfective labeled.
Thus. these results indicate that nucleotide a?inity bind
ing sites suitable for photoa?inity nucleotide labeling are

antibody was used as the non-speci?c cell inhibitor.

These results. using different speci?c mounts of unlabeled
antibody ranging from 0 to 10 pg are shown in FIG. 4. It can
be clearly seen from these results that the cold (unlabeled)

comprised on antibodies of different species. origin and an

antibody of different isotype. Moreover. these results indi~

3H1 antibody inhibits the binding of isotope labeled 3H1.
10

Example 6

While the invention has been described in the terms of

Antibody

various preferred embodiments. the skilled artisan will
appreciate that various modi?cations. substitutions.
omissions, and changes may be made without departing
from the spirit thereof. Accordingly. it is intended that the
scope of the present invention be limited solely by the scope
of the following claims. including equivalents thereof.

The binding of isotope labeled anti-B cell lymphoma
idiotypic antibody to live tumor cells was tested.

Speci?cally. 1o6 SU-DHL-4 cells were incubated with dif
ferent mounts of unlabeled antibody and the same mount of

labeled antibody (3 mg/tube) for 30 minutes at 4° C. Cells

What is claimed is:
20

medium). Binding of ynP-labeled antibody was detected by
liquid scintillation counting.

with an effective amount of a nucleotide photoaf?nity com

25

Characterization of Labeled Antibodies by

compound is an ATP- or GTP-analog photoa?inity com

pound.

Isoelectr'ic Focussing

3. The nucleotide photoa?inity compound-antibody con

Labeled antibodies were also characterized by isoelectric

jugate of claim 1. wherein the nucleotide photoaf?nity
compound site-speci?cally attaches to one or more sites

having high at?nity for purine. azidopun'ne or heterocyclic
35

isoelectric focusing standards used were:

A=cytochrome C (pI 9.6). B=equine myoglobin (pI 7.0).
C=bovine carbonic anhydrase (pI 6.0). D =phycocyanin

40

(pI 4.65) (lane 10).
The unlabeled antibody is shown in lane 1.

SICS antibody (5 pg) was photolyzed by 3.125 pm (lane
9). 6.25 pm (lane 8). 12.5 mm (lane 7). 25 pm (lane 6). 50 pm

(lane 5). 100 pm (lane 4). 200 pm (lane 3). and 400 pm (lane
2) [7”Pl-8-NS ATP.

45

Example 8
Labeling. of Antibodies of Di?’erent Species and

Isotype Using [7”P1-8-N; ATP

50

ATP and benzoylphenone-ATP.
5. The nucleotide photoa?inity compound-antibody con
jugate of claim 1. wherein said antibody is selected from the
group consisting of polyclonal antibodies. monoclonal
antibodies. recombinant antibodies. chimeric antibodies.
bispeci?c antibodies and fragments thereof.
6. The nucleotide photoat?nity compound-antibody con
jugate of claim 1. wherein the nucleotide photoa?inity
compound is covalently bound or complexed to a reporter.

group consisting of radiolabels. enzymes. chromophores.
polynucleotides. and ?uorochromes.
8. The nucleotide photoa?‘inity compound-antibody con
jugate of claim 6. wherein the reporter is a radiolabel.
9. The nucleotide photoat?nity compound-antibody con

rmn-ine. goat, human and rabbit antibodies were labeled with
SS

in accordance with Example 1. The same amount (3 pg) of

the respective antibodies [murine monoclonal IgGl. SD10
(lane 1). murine myeloma IgGl (lane 2). murine myeloma
IgA (lane 3). goat Ig (lane 4). goat (Fab)2 fragments (lane 5).
human myeloma IgGl K (lane 6). human myeloma IgGl 1
(lane 7), human myeloma IgM (lane 8). murine monoclonal
IgM (lane 9). murine monoclonal IgG2b. SIC5 (lane 10)]

jugate of claim 1, wherein site-speci?c photoinsertion is
e?‘ected using ultraviolet light.
10. The nucleotide photoa?inity compound-antibody con
jugate of claim 1. wherein the nucleotide photoaf?nity
compound is covalently bound to or complexed to an
etfector molecule.
11. The nucleotide photoa?nity compound-antibody con
jugate of claim 10. wherein the eifector is selected ?om the
group consisting of proteins DNA. RNA. DNA or RNA

was photolyzed in the presence of 200 pm [y”P]-8-N3 ATP

and separated by 8-16% gradient SDS-PAGE. Following
electrophoresis. the gel was stained with Coomassie Blue,
dried and autoradiographed. These results are contained in
FIG. 7.

bases having a similar structure to purine.
4. The nucleotide photoa?inity compound-antibody con
jugate of claim 2, wherein the ATP- or GTP-analog is
selected from the group consisting of 2-azido-ATP, S-azido

7. The nucleotide photoa?inity compound-antibody con
jugate of claim 6. wherein the reporter is selected from the

In this experiment. antibodies of different species. origin
and isotype were labeled with [y32P]-8-N3 ATP. Speci?cally.

[f2Pl-8-N3 ATP. Labeling was again eifected substantially

one or more nucleotide binding sites in the antibody con

tained in the sample.
2. The nucleotide photoa?inity compound-antibody con
jugate of claim 1. wherein said nucleotide photoa?inity

Example 7

focusing. A representative isoelectric focusing pattern of a
labeled and unlabeled antibody is found in FIG. 6.
Isoelectric focusing was e?’ected at a pH ranging from 3
to 10 using SICS antibodies which had been photolabeled
with increasing concentrations of [*f’Pl-S-N3 ATP. The

l. A nucleotide photoa?inity compound-antibody conju
gate produced by reacting an antibody-containing sample
pound under conditions which provide for the site-speci?c
photoinsertion of said nucleotide photo-affinity compound at

These results are contained in FIG. 5. It can be clearly

seen that the unlabeled antibody etfectively inhibits binding
of the isotope labeled antibody to tumor cells.

may be effectively labeled using nucleotide photoa?inity

probes.

Cell-Surface Competition Binding of Labeled SD10

were then washed using 20 % fetal calf serum (FCS)

cate that antibody fragments. as well as intact antibodies

containing complexes toxins. cytokines. chelatin agents. and
65

radiolabels.

12. The nucleotide photoa?inity compound-antibody con
jugate of claim 10. wherein the effector is a heavy metal.

5,693,764
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13. The nucleotide photoa?inity compound-antibody conjugate of claim 12. wherein the heavy metal is radioactive.
14. The nucleotide photoa?inity compound-antibody conjugate of claim 12, wherein the heavy metal is iron or

15. The nucleotide photoaf?nity compound-antibody con
jugate of claim 13, wherein the radioactive heavy metal is
111In“.

mercury
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